Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Teva Pharmaceutical Industries EV-to-EBITDA?
Teva Pharmaceutical IndustriesLTS:0LER +1.96%45 EV-to-EBITDA is 21.61 as of Aug. 13, 2026, which is 55% above its 10-year median of 13.95. GuruFocus rates LTS:0LER with a GF Score™ of 45/100 and a GF Value™ of $20.98 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 734 Drug Manufacturers companies, Teva Pharmaceutical Industries ranks worse than 69.35% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Teva Pharmaceutical Industries's enterprise value is $56,052 Mil.
Teva Pharmaceutical Industries's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $2,594 Mil. Therefore, Teva Pharmaceutical Industries's EV-to-EBITDA for today is 21.61.
The historical rank and industry rank for Teva Pharmaceutical Industries's EV-to-EBITDA or its related term are showing as below:
LTS:0LER'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -4269.2 Med: 13.95 Max: 321.67
Current: 21.75
During the past 13 years, the highest EV-to-EBITDA of Teva Pharmaceutical Industries was 321.67. The lowest was -4269.20. And the median was 13.95.
LTS:0LER's EV-to-EBITDA is ranked worse than 69.35% of 734
companies
in the Drug Manufacturers industry
Industry Median: 13.355
vs LTS:0LER: 21.75
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Teva Pharmaceutical Industries's PE Ratio (TTM) for today is calculated as:
Teva Pharmaceutical Industries's share price for today is $36.50.
Teva Pharmaceutical Industries's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.600.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0LER vs ZTS, UTHR, VTRS: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Teva Pharmaceutical Industries EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Teva Pharmaceutical Industries's EV-to-EBITDA falls into.
Teva Pharmaceutical Industries's current Enterprise Value is $56,052 Mil.
Teva Pharmaceutical Industries's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,594 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Teva Pharmaceutical Industries (LTS:0LER) has a EV-to-EBITDA of 21.61 as of Aug. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Teva Pharmaceutical Industries. This is 55% above median its historical median of 13.95. According to the industry distribution chart, Teva Pharmaceutical Industries ranks #509 out of 734 companies in the Drug Manufacturers industry, placing it in the top 69.3%.
Is Teva Pharmaceutical Industries' EV-to-EBITDA too high?
Teva Pharmaceutical Industries' current EV-to-EBITDA of 21.61 is 55% above median its 10-year median of 13.95. The Drug Manufacturers industry median EV-to-EBITDA is 13.36. Teva Pharmaceutical Industries' value of 21.61 is 61.8% above this industry median. Based on the distribution chart, Teva Pharmaceutical Industries ranks #509 out of 734 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Teva Pharmaceutical Industries has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Teva Pharmaceutical Industries' EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Teva Pharmaceutical Industries ranks #509 out of 734 companies for EV-to-EBITDA. This places Teva Pharmaceutical Industries in the lower half of its industry. The industry median EV-to-EBITDA is 13.36. Teva Pharmaceutical Industries' value of 21.61 is 61.8% above this benchmark. While the company's 10-year median is 13.95 vs. the industry median of 13.36, Teva Pharmaceutical Industries has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.36, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Teva Pharmaceutical Industries's current EV-to-EBITDA of 21.61 is 61.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Teva Pharmaceutical Industries. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Teva Pharmaceutical Industries's current EV-to-EBITDA is 21.61, which is 55% above median its own 10-year median of 13.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Teva Pharmaceutical Industries stock overvalued right now?
Based on GuruFocus' analysis, Teva Pharmaceutical Industries (LTS:0LER) is currently considered Significantly Overvalued. The stock's GF Value™ is $20.98, compared to a current price of $36.50 — trading 74% above its estimated fair value. The current EV-to-EBITDA is 21.61, which is 55% above median its 10-year median of 13.95 and 61.8% above the Drug Manufacturers industry median of 13.36. Teva Pharmaceutical Industries' overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Teva Pharmaceutical Industries (LTS:0LER), the current EV-to-EBITDA is 21.61 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Teva Pharmaceutical Industries (LTS:0LER) Overvalued in 2026?
Based on GuruFocus' analysis, Teva Pharmaceutical Industries stock appears to be overvalued.
The current stock price of $36.50 is trading 74% above its estimated GF Value™ of $20.98.
GuruFocus considers Teva Pharmaceutical Industries to be Significantly Overvalued.
Key valuation signals for LTS:0LER:
EV-to-EBITDA: 21.61 (55% above median its 10-year median of 13.95)
GF Value™: $20.98 vs. price of $36.50 (74% above fair value)
Industry Position: 61.8% above the Drug Manufacturers median (#509 of 734)
No single metric tells the full story. See the LTS:0LER stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
45GF Score
Get the complete analysis for LTS:0LER
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0LER has been successfully added to your 
